We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

The U.S. Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

The second person ever has received a transplant with a genetically modified pig kidney.

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...